<DOC>
	<DOC>NCT01740986</DOC>
	<brief_summary>Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients</brief_summary>
	<brief_title>Safety and Efficacy of SA09012 in Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Diagnosis or presence of asthma within 3 months of the prestudy visit 1. Increase in PEF ≥ 20% or ≥ 60L/min from baseline value after taking Bronchodilator at screening or within the 3 months of the prestudy visit 2. Increase in FEV1 ≥ 12% and ≥ 200mL from baseline value after taking Bronchodilator at screening or within the 3 months of the prestudy visit FEV1 or PEF between 60% and 85% of the predicted value at screening or within the 3 months of the prestudy visit Having signed an informed consent Patient who has severe asthma Patient who has any significant medical condition that might compromise patient safety, interfere with evaluation or preclude completion of the study other protocoldefined inclusion/exclusion criteria may apply Patient with an AST or ALT &gt; 2x ULN (upper limit of normal) in the screening visit Patient with more than 10 pack year of cigarettes history</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Asthma</keyword>
</DOC>